Rest-Of-Europe Protein Expression Market Size, Share,Trends, Growth Analysis Report, 2031

Name: Rest-Of-Europe Protein Expression Market Size, Share,Trends, Growth Analysis Report, 2031
Creator: MarketsandMarkets

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of Europe Protein Expression Market analysis

Part of: Protein Expression Market (Global)

The Rest Of Europe Protein Expression Market was valued at $189.1 Million in 2026 and projected to reach to $276.3 Million by 2031, representing a compound annual growth rate of 7.9%. Rest Of Europe's protein expression market is positioned for steady growth through 2031, driven by expanding biopharmaceutical pipelines and increased investment in contract research organizations.

Rest Of Europe Protein Expression Market (2026-2031) : Size and Share

CAGR of

USD Million

Rest Of Europe Protein Expression Market Trends and Insights

This 7.9% compound annual growth rate reflects increasing investment in biopharmaceutical research and development across the region.
Rest Of Europe is benefiting from rising demand for recombinant proteins, monoclonal antibodies, and therapeutic biologics, driven by both academic institutions and commercial biotech enterprises. The protein expression landscape in Rest Of Europe is characterized by growing adoption of advanced expression systems, including mammalian cell cultures, insect cell systems, and microbial platforms.
Rest Of Europe's market growth is supported by favorable regulatory frameworks, collaborative research initiatives, and expanding manufacturing capabilities.
Between 2026 and 2031, Rest Of Europe is expected to see accelerated investment in contract manufacturing organizations (CMOs) and contract research organizations (CROs) specializing in protein production. Rest Of Europe's competitive positioning within the broader European market reflects strong scientific infrastructure and increasing commercialization of protein-based therapeutics.
The region's market trajectory demonstrates sustained momentum in biotechnology innovation and protein engineering applications across pharmaceutical and diagnostic sectors..

Key Market Statistics

CAGR (2026-2031) 7.9% CAGR
Market Size, 2026 ~USD 189.1 Million
Forecast, 2031 ~USD 276.3 Million
Country Rest Of Europe

Rest Of Europe Protein Expression Market Overview

Market Valuation Growth :

Rest Of Europe's protein expression market is valued at $189.1 million in 2026, with projections reaching $276.3 million by 2031, representing a robust 7.9% CAGR over the forecast period.

Biopharmaceutical Investment Surge :

Increasing R&D investments across Rest Of Europe are driving demand for advanced protein expression technologies, supporting the development of innovative biopharmaceutical solutions and therapeutic proteins.

Recombinant Protein Demand :

Rising adoption of recombinant proteins and monoclonal antibodies in Rest Of Europe reflects growing therapeutic applications and the region's commitment to advancing biologics manufacturing capabilities.

Regional Competitive Advantage :

Rest Of Europe benefits from established biotech infrastructure, skilled workforce, and regulatory frameworks that support protein expression innovation and commercial scale-up operations.

Rest Of Europe Protein Expression Market Dynamics

The region's mature biotech ecosystem and proximity to major pharmaceutical hubs create favorable conditions for market expansion.
Growing demand for therapeutic proteins, particularly monoclonal antibodies and recombinant biologics, continues to fuel market development across the region. Key growth drivers include rising healthcare expenditures, supportive regulatory environments, and technological advancements in expression systems.
Rest Of Europe's focus on personalized medicine and advanced therapeutics will sustain market momentum.
Strategic collaborations between academic institutions and industry players are expected to accelerate innovation and commercialization of protein-based therapeutics throughout the forecast period..

Related Ecosystem

Biotechnology

Top Technologies

Reagents
Polymerase Chain Reaction (PCR)
Stem Cells
Assay Kits
Flow Cytometers

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.

Key Takeaways

Rest Of Europe's protein expression market will grow from $189.1M (2026) to $276.3M (2031) at a 7.9% CAGR.
Rest Of Europe is experiencing increased adoption of mammalian, insect, and microbial expression systems for therapeutic protein production.
Rest Of Europe's growth is driven by expanding CMO/CRO capabilities and rising biopharmaceutical R&D investment across the region.
Rest Of Europe maintains strong competitive positioning through advanced scientific infrastructure and favorable regulatory environments supporting protein-based therapeutics.

Protein Expression Market Report Scope

Report Metric	Details
Base Year	2026
Fastest Growing Segment	SOFTWARE (Type)
Forecast Period	2026�2031
Growth Rate	CAGR of 8.3% from 2026 to 2031
Largest Segment	PRODUCTS (Offering)
Market Size Base Year (Billions)	~USD 5.13 (2026)
Revenue Forecast (Billions)	~USD 7.65 (2031)
Segments Covered	Offering, Type, End User, Workflow, Scale Of Operation, Protein Modality, Application

Rest Of Europe Protein Expression Market Report Segmentation

7 segment dimensions are covered across the global market.

By Offering

Products
Services

By Type

Algal & Plant-Based Expression Systems
Algal-Based Expression Systems
Analytical Instruments
Bacillus Systems
Baculovirus Systems
Bioreactors & Fermenters
Cell-Free Expression Systems
Cho Cell Systems
Chromatography & Purification Consumables
Chromatography Systems
Cld Services
Cloning & Mutagenesis Kits
Competent Cells
Consumables
Culture Media & Supplements
Custom Protein Expression Services
E. Coli Lysate-Based Systems
E. Coli Systems
Expression Kits
Expression Vectors & Plasmids
Filtration & Separation Consumables
Filtration Systems
Gene Synthesis & Cloning Services
Hek 293 Cell Systems
Insect Cell Expression Systems
Instruments
Kits
Liquid Handling & Automation Systems
Mammalian Cell Expression Systems
Other Cell-Free Expression Systems
Other Consumables
Other Insect Cell Expression Systems
Other Instruments
Other Kits
Other Mammalian Cell Expression Systems
Other Prokaryotic Expression Systems
Other Reagents
Other Yeast Expression Systems
Pichia Systems
Process Development & Scale-Up Services
Prokaryotic Expression Systems
Reagents
Saccharomyces Systems
Software
Transduction & Transfection Reagents
Yeast Expression Systems

By End User

Academic & Research Institutes
Cros & Cdmos
Other End Users
Pharmaceutical & Biotechnology Companies

By Workflow

Cloning & Transfection
Extraction, Purification, And Characterization
Transcription, Translation, And Post-Translational Modification (Ptm)

By Scale Of Operation

Discovery & Research Scale
Preclinical & Characterization Scale
Process Development & Pilot Scale

By Protein Modality

Enzymes & Catalytic Proteins
Monoclonal Antibodies & Derivatives
Other Proteins
Recombinant Therapeutic Proteins
Vaccines

By Application

Diagnostic Applications
Industrial Applications
Research Applications
Therapeutic Applications

Target Audience

Biopharmaceutical Companies : Rest Of Europe-focused biotech firms need regional market data to optimize protein expression investments, assess manufacturing expansion opportunities, and align R&D strategies with local market demand.
Contract Research Organizations (CROs) : CROs operating in Rest Of Europe require market insights to identify service expansion opportunities, benchmark pricing strategies, and understand regional demand for protein expression capabilities.
Equipment & Technology Providers : Suppliers of protein expression systems and reagents need Rest Of Europe-specific data to target sales efforts, develop localized solutions, and forecast regional revenue potential.
Investment & Private Equity Firms : Investors evaluating biotech opportunities in Rest Of Europe require detailed market analysis to assess portfolio company growth potential, identify acquisition targets, and evaluate regional market attractiveness.
Healthcare Policy & Regulatory Bodies : Government agencies and regulatory organizations in Rest Of Europe need market intelligence to inform healthcare policy, support biopharmaceutical industry development, and guide R&D funding initiatives.

Key Companies in the Rest Of Europe Protein Expression Market

Company	HQ	Ownership	Strongest segments
PATHEON INC	Netherlands	Private Company	Drug Product Services (finished dosage manufacturing & packaging),Pharmaceutical Development Services,Drug Substance Services (small- and large-molecule APIs),
NANOSTRING TECHNOLOGIES, INC	United States	Private Company	nCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna and other in vitro diagnostic kits,
BIOGEN	United States	Public Company	Multiple Sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SPINRAZA and rare neuromuscular (SPINRAZA, QALSODY, SKYCLARYS),Alzheimer�s and neuropsychiatry (LEQEMBI, ZURZUVAE),
SIGMA-ALDRICH CORPORATION	United States	Private Company	Pharma and biopharma manufacturing (media, filtration, critical raw materials, safety testing),Research reagents and molecular biology (chemicals, biochemicals, functional genomics, protein biology),Analytical chemistry, diagnostics, and industrial microbiology,
VIVA BIOTECH LTD	China	Public Company	Discovery biology & structural biology services,Medicinal and synthetic chemistry & CADD,CDMO & CMC/filing services,
CODEXIS, INC.	United States	Public Company	Biopharma process enzymes and custom engineering (CodeEvolver-based),ECO Synthesis and nucleic acid manufacturing solutions,Other life science and industrial enzyme applications,
MAXCYTE, INC	United States	Public Company	ExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables,
THERMO FISHER SCIENTIFIC INC.	United States	Public Company	Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAA	Germany	Public Company	Life Science (reagents, consumables, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, delivery equipment),
DANAHER CORPORATION	United States	Public Company	Biotechnology (bioprocessing and bioproduction),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments and consumables),
AGILENT TECHNOLOGIES, INC.	United States	Public Company	Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
SARTORIUS AG	Germany	Public Company	Bioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical solutions (BLI, cytometry screening, PAT, live-cell imaging, SPR),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
GENSCRIPT	Hong Kong	Public Company	Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
TAKARA BIO INC.	Japan	Private Company	Genetic and cellular research reagents,Instruments and cellular analysis devices,In vitro diagnostics (including COVID-19),
BIO-RAD LABORATORIES, INC.	United States	Public Company	Clinical Diagnostics,Life Science Research Instruments and Reagents,Other / Software and Services,
QIAGEN	Netherlands	Public Company	Sample technologies (extraction and purification consumables/instruments),PCR and enzymes (qPCR/dPCR instruments and reagents),Molecular diagnostic assays (TB, oncology, sexual and reproductive health, transplant/viral load),
CHARLES RIVER LABORATORIES	United States	Public Company	Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
CORNING INCORPORATED	United States	Public Company	Optical communications (fiber, cable, hardware, equipment),Display glass substrates (LCD/OLED),Specialty materials and mobile consumer electronics glass,
LONZA	Switzerland	Public Company	Integrated Biologics (mammalian and drug product CDMO),Advanced Synthesis (small molecules, HPAPIs, ADCs, bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
FUJIFILM HOLDINGS CORPORATION	Japan	Public Company	Healthcare (medical systems, CDMO, pharma, regenerative, cosmetics/supplements),Electronics (display, semiconductor, image sensors, functional films, storage),Business Innovation (office equipment, document services, graphic communications),
SYNGENE INTERNATIONAL LIMITED	India	Public Company	Discovery Services (chemistry, biology, computational),Development Services (preclinical, CMC, clinical development),Biologics and Specialty Modalities,
LGC LIMITED	South Korea	Public Company	Ethylene-based synthetic resins (PE, EVA, LLDPE, UNIQABLE),Styrene-based resins (ABS, ASA, PS, EPS, SAN),Polycarbonate and engineering plastics (LUMID/LUXY, LUMILOY, LUPOL, LUPOY, etc.),

PATHEON INC

Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.

NANOSTRING TECHNOLOGIES, INC

NanoString Technologies, Inc is a United States-based private company founded in 2003 with 550 employees specializing in life sciences technology.

BIOGEN

Biogen is a United States-based public company founded in 1978 with 7,500 employees engaged in biotechnology and pharmaceutical development.

SIGMA-ALDRICH CORPORATION

Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees providing life sciences products and services.

VIVA BIOTECH LTD

Viva Biotech Ltd is a China-based public company founded in 2008 with 2,169 employees providing drug discovery and development services.

CODEXIS, INC.

Codexis, Inc is a United States-based public company founded in 2002 with 146 employees focused on enzyme engineering and biocatalysis.

MAXCYTE, INC

MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees specializing in cell engineering technology.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc is a United States-based public company founded in 1956 with 125,000 employees serving the life sciences and laboratory sectors globally.

MERCK KGAA

Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees operating as a diversified pharmaceutical and chemical company.

DANAHER CORPORATION

Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees engaged in life sciences, diagnostics, and environmental solutions.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

SARTORIUS AG

Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees specializing in laboratory and bioprocess equipment.

GENSCRIPT

GenScript is a Hong Kong-based public company founded in 2002 with 6,165 employees providing biotechnology research services and products.

TAKARA BIO INC.

Takara Bio Inc is a Japan-based private company founded in 2002 with 1,779 employees specializing in biotechnology research tools and services.

BIO-RAD LABORATORIES, INC.

Bio-Rad Laboratories, Inc is a United States-based public company founded in 1952 with 7,450 employees manufacturing life sciences research and clinical diagnostics products.

QIAGEN

Qiagen is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research solutions.

CHARLES RIVER LABORATORIES

Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services.

CORNING INCORPORATED

Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees manufacturing specialty glass and materials for life sciences applications.

LONZA

Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services.

FUJIFILM HOLDINGS CORPORATION

Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating across imaging, pharmaceuticals, and life sciences sectors.

SYNGENE INTERNATIONAL LIMITED

Syngene International Limited is an India-based public company founded in 1993 with 6,692 employees providing drug discovery and development services.

LGC LIMITED

LGC Limited is a South Korea-based public company founded in 1947 with 14,019 employees operating in life sciences and analytical testing services.

Reasons to Buy this Report

Regional Market Sizing : Obtain precise valuation data specific to Rest Of Europe's protein expression market, including 2026 baseline ($189.1M) and 2031 forecasts ($276.3M), enabling accurate regional business planning and investment decisions.
Growth Trajectory Analysis : Understand the 7.9% CAGR specific to Rest Of Europe, allowing you to benchmark regional performance against global trends (8.3%) and identify market opportunities unique to the region.
Competitive Landscape Intelligence : Gain insights into Rest Of Europe's biopharmaceutical R&D investments, manufacturing capabilities, and regulatory environment to inform market entry strategies and competitive positioning.
Segment Demand Drivers : Access detailed analysis of recombinant protein, monoclonal antibody, and therapeutic protein demand patterns specific to Rest Of Europe's healthcare and biotech sectors.
Strategic Investment Guidance : Leverage region-specific market intelligence to identify high-growth opportunities, partnership prospects, and expansion strategies tailored to Rest Of Europe's evolving protein expression landscape.

Frequently asked questions

What is the projected market size for protein expression in Rest Of Europe by 2031?

Rest Of Europe's protein expression market is projected to reach $276.3 million by 2031, growing from $189.1 million in 2026.

What is the CAGR for Rest Of Europe's protein expression market?

Rest Of Europe's protein expression market is expected to grow at a compound annual growth rate of 7.9% between 2026 and 2031.

Which expression systems are most commonly used in Rest Of Europe?

Rest Of Europe utilizes mammalian cell cultures, insect cell systems, and microbial platforms as primary protein expression technologies for therapeutic and research applications.

What factors are driving growth in Rest Of Europe's protein expression market?

Rest Of Europe's market growth is driven by increased biopharmaceutical R&D investment, expanding CMO/CRO capabilities, rising demand for recombinant proteins and monoclonal antibodies, and favorable regulatory frameworks.

How does Rest Of Europe's protein expression market compare to other European regions?

Rest Of Europe maintains competitive positioning within Europe through strong scientific infrastructure, collaborative research initiatives, and increasing commercialization of protein-based therapeutics and diagnostic applications.

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the protein expression market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global protein expression market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Protein Expression Market
Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the protein expression market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Protein Expression Market : Top-Down and Bottom-Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

The protein expression market encompasses the technologies, products, and services required for protein production and analysis. This market includes various expression systems (mammalian, bacterial, yeast, algal, insect, and cell-free), reagents and instruments for transfection and cloning, growth reagents for cell culture during translation, and reagents and kits for downstream processes such as purification and characterization. It serves industries such as pharmaceuticals, biotechnology, academic & research institutes, CROs & CDMOs, and other industrial users, supporting applications in drug discovery, therapeutic development, and biochemical research, as well as other industries such as food and beverages, cosmetics, and textiles, among others.

Key Stakeholders

Protein Expression Instrument & Reagent Manufacturers
Suppliers of Expression Systems
National and regional research boards and organizations
Research & development companies
Clinical research organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Biotechnology companies
Research laboratories & academic institutes
Market research & consulting firms
Regulatory bodies

Report Objectives

To define, describe, and forecast the protein expression market by offering, type, workflow, scale of operation, protein modality, application, product end user, service end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall protein expression market
To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia, United Arab Emirates, and the Rest of GCC) and the Rest of Middle East], and Africa
To profile the key players and analyze their market shares and core competencies
To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Customization Options

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

Further breakdown of the Rest of Europe protein expression market, by country
Further breakdown of the Rest of Asia Pacific protein expression market, by country

Segment Analysis

Cross-segment analysis

Get the Full Protein Expression Market Report

Full forecast, segment splits, and company analysis for all Protein Expression Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)